logo

For the Inventor, By the Inventor

Tokyo, Japan

Ribomic Inc.


USPTO Granted Patents = 14

% Expired Patents = 50.0



Forward Citations = 32

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Yoshikazu Nakamura (10 out of 14 patents)

silverMedal Shin Miyakawa (6 out of 7 patents)

bronzeMedal Ling Jin (5 out of 6 patents)

4.  Masatoshi Fujiwara (5 out of 32 patents)

5.  Takashi Matsui (3 out of 113 patents)

6.  Hisanao Hiramatsu (3 out of 3 patents)

7.  Sadatoshi Sakuma (3 out of 15 patents)

8.  Akio Suzumura (2 out of 9 patents)

9.  Satoko Yamazaki (2 out of 2 patents)

10.  Masahiro Muraguchi (2 out of 2 patents)

11.  Jinyan Wang (2 out of 2 patents)

12.  Kazuteru Aoki (2 out of 2 patents)

13.  Akira Ishiguro (1 out of 6 patents)

14.  Kenji Kadomatsu (1 out of 12 patents)

15.  Ping Mu (1 out of 1 patent)


14 patents:

1. 12674170 - APTAMER FOR IL-21 AND USE THEREOF (2026-07-07),
2. 11639503 - Anti-chymase aptamer and use for same (2023-05-02),
3. 11473089 - Aptamer for ADAMTS5 and use for aptamer for ADAMTS5 (2022-10-18),
4. 10260070 - Aptamer for NGF and use thereof (2019-04-16),
5. 9987298 - Aptamer for FGF2 and use thereof (2018-06-05),
6. 9567589 - NGF aptamer and application thereof (2017-02-14),
7. 9506070 - Aptamer against midkine and applications thereof (2016-11-29),
8. 9175292 - Aptamer for NGF and use thereof (2015-11-03),
9. 9012420 - Aptamer for chymase, and use thereof (2015-04-21),
10. 8772259 - Aptamer to FGF2 and use thereof (2014-07-08),
11. 8716230 - Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells (2014-05-06),
12. 8637656 - Nucleic acid capable of binding to immunoglobulin G and use thereof (2014-01-28),
13. 8128934 - Method for treatment or prevention of disease associated with functional disorder of regulatory T cell (2012-03-06),
14. 8080649 - Aptamer against midkine and use thereof (2011-12-20),
Company Overview
Ribomic Inc. is a biotechnology company based in Tokyo, Japan, specializing in the development of innovative RNA-targeting therapeutics. The company focuses on harnessing its proprietary ribonucleic acid (RNA) technology platform to create novel treatments for various diseases, including cancer and infectious diseases. Ribomic's research emphasizes precision medicine, aiming to address unmet medical needs through targeted RNA modulation, thereby advancing the field of molecular therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#1,599 in Tokyo

#3,584 in Japan

#42,290 in the World

Tokyo, JP
Tokyo, Japan

Ribomic Inc.

Forward Citations = 32

20 inventors:

goldMedal Yoshikazu Nakamura (10 out of 14 patents)

silverMedal Shin Miyakawa (6 out of 7 patents)

bronzeMedal Ling Jin (5 out of 6 patents)

4.  Masatoshi Fujiwara (5 out of 32 patents)

5.  Takashi Matsui (3 out of 113 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ribomic Inc.. Retrieved from https://idiyas.com/company/ribomic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…